Singapore markets open in 8 hours 38 minutes
  • Straits Times Index

    3,287.95
    +5.98 (+0.18%)
     
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • BTC-USD

    42,342.44
    -960.20 (-2.22%)
     
  • CMC Crypto 200

    1,015.74
    -9.99 (-0.97%)
     
  • FTSE 100

    7,612.02
    +69.07 (+0.92%)
     
  • Gold

    1,818.30
    +1.80 (+0.10%)
     
  • Crude Oil

    83.97
    +0.15 (+0.18%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • Nikkei

    28,333.52
    +209.24 (+0.74%)
     
  • Hang Seng

    24,218.03
    -165.29 (-0.68%)
     
  • FTSE Bursa Malaysia

    1,542.92
    -12.41 (-0.80%)
     
  • Jakarta Composite Index

    6,645.05
    -48.35 (-0.72%)
     
  • PSE Index

    7,223.83
    -37.51 (-0.52%)
     

Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, has been alerted to falsified information circulating on social media relating to the company’s planned poster presentation for the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250 at the San Antonio Breast Cancer Symposium (SABCS). The falsified poster image was not released or authorized by the company.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

CONTACT: Contact: Eva Stroynowski Vice President, Communications and Investor Relations eva@olema.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting